Patents Assigned to Daiichi Sankyo Company, Limited
  • Publication number: 20220143009
    Abstract: A pharmaceutical composition and a therapeutic method wherein an antibody-drug conjugate and an immune checkpoint inhibitor are administered in combination, and the antibody-drug conjugate is an antibody-drug conjugate in which a drug-linker represented by the following formula (wherein A represents the connecting position to an antibody) is conjugated to the antibody via a thioether bond; and a pharmaceutical composition and a therapeutic method for use in treatment of a disease that can be ameliorated through an antitumor immunity-activating effect wherein the antibody-drug conjugate is included.
    Type: Application
    Filed: January 27, 2022
    Publication date: May 12, 2022
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Tomomi IWATA, Chiaki ISHII, Teiji WADA, Saori ISHIDA, Yasuki KAMAI
  • Publication number: 20220144765
    Abstract: An object of the present invention is to find a novel pharmaceutical that has an excellent tryptophanase inhibitory effect and suppresses worsening of renal function to preserve the kidney by reducing production of indoxyl sulfate in the blood. The present invention provides a pharmaceutical composition containing, as an active ingredient, a compound represented by the following formula, or a pharmacologically acceptable salt thereof: wherein R1 and R2 are the same or different, and represent a C1-C6 alkyl group or the like, and Ar represents an optionally substituted phenyl group or an optionally substituted thienyl group.
    Type: Application
    Filed: January 26, 2022
    Publication date: May 12, 2022
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Tsuyoshi Soneda, Yuji Nakamura, Koji Matsumoto, Naomi Tanaka, Taichi Fukunaga
  • Patent number: 11319345
    Abstract: Disclosed are compositions and method related to variants of SPINK2 that bind to targets other than an endogenous target of SPINK2. In one embodiment, a peptide is provided that comprises the amino acid sequence SEQ ID NO: 1. In further embodiments, an amino acid sequences encoded by nucleotide positions 4 to 42 and/or nucleotide positions 94 to 189 in the nucleotide sequence of SEQ ID NO: 14 flank the amino terminus and the carboxyl terminus, respectively, of the amino acid sequence. In another embodiment, a peptide is provided that comprises an amino acid sequence derived from the amino acid sequence of SEQ ID NO: 1 in which a conservative substitution, deletion, addition and/or insertion of 1 to 5 (inclusive) amino acids has occurred at amino acids other than the 1st Xaa to the 12th Xaa counting from the amino terminus.
    Type: Grant
    Filed: January 30, 2020
    Date of Patent: May 3, 2022
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Daisuke Nishimiya, Ryuji Hashimoto
  • Patent number: 11318124
    Abstract: The present invention provides a medicament comprising a compound represented by general formula (1) which has Axl inhibitory activity, and an EGFR tyrosine kinase inhibitor in combination, and a method for treating cancer using this combination. The present invention provides an excellent medicament and method for treating cancer which is highly effective for inhibiting resistance to an EGFR tyrosine kinase inhibitor in cancer treatment, and causes less adverse reactions such as weight loss.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: May 3, 2022
    Assignee: Daiichi Sankyo Company, Limited
    Inventor: Takeshi Jimbo
  • Patent number: 11318212
    Abstract: A method for producing a compound represented by formula (C) wherein R1 represents an amino group protected with a protecting group, the method comprising a step of subjecting a compound represented by formula (B) wherein R1 represents the same meaning as above, to intramolecular cyclization to convert the compound into the compound represented by formula (C).
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: May 3, 2022
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Yoshio Nishi, Kohei Sakanishi, Shigeru Noguchi, Tadahiro Takeda
  • Publication number: 20220125943
    Abstract: The present invention provides a novel antibody-pyrrolodiazepine derivative and a novel antibody-pyrrolodiazepine derivative conjugate using the same, and a novel CLDN6 and/or CLDN9 antibody.
    Type: Application
    Filed: December 6, 2021
    Publication date: April 28, 2022
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Narihiro TODA, Yusuke OTA, Fuminao DOI, Masaki MEGURO, Ichiro HAYAKAWA, Shinji ASHIDA, Takeshi MASUDA, Takashi NAKADA, Mitsuhiro IWAMOTO, Naoya HARADA, Tomoko TERAUCHI, Daisuke OKAJIMA, Kensuke NAKAMURA, Hiroaki UCHIDA, Hirofumi HAMADA
  • Patent number: 11312776
    Abstract: This application provides: an antibody which specifically binds to an ALK2 protein and has an activity of inhibiting BMP signal transduction mediated by ALK2; a method for producing the antibody; and a pharmaceutical composition comprising the antibody, for treating and/or preventing ectopic ossification and/or bone dysplasia, anemia, or diffuse intrinsic pontine glioma (DIPG).
    Type: Grant
    Filed: August 19, 2019
    Date of Patent: April 26, 2022
    Assignees: Saitama Medical University, Daiichi Sankyo Company, Limited
    Inventors: Takenobu Katagiri, Kenji Osawa, Sho Tsukamoto, Shinnosuke Tsuji, Yoshirou Kawaguchi, Kensuke Nakamura
  • Patent number: 11311524
    Abstract: The present invention provides a pharmaceutical composition containing an inhibitor selected from the group consisting of an EZH1 inhibitor, an EZH2 inhibitor and an EZH1/2 dual inhibitor as an active ingredient, for use in treating HTLV-1-associated myelopathy. The present invention provides a pharmaceutical composition for use in treating HTLV-1-associated myelopathy, containing a 1,3-benzodioxole derivative or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: January 18, 2018
    Date of Patent: April 26, 2022
    Assignees: DAIICHI SANKYO COMPANY, LIMITED, ST. MARIANNA UNIVERSITY SCHOOL OF MEDICINE
    Inventors: Yoshihisa Yamano, Natsumi Ueda, Kazushi Araki
  • Patent number: 11308607
    Abstract: A method of producing a tablet in which an uncoated tablet is coated by a coating agent, the method including: a coating process of coating uncoated tablets with a coating agent by spray coating the coating agent onto tablets that are churned and tumbled inside a container, and drying the tablets inside the container by supplying drying air into the container and exhausting air from the container, wherein spray coating conditions, including air supply temperature, air supply rate, and spray speed, are controlled according to the weight of the coating agent with which the uncoated tablets are coated, such that the humidity of air exhausted during spray coating is within a range of from 14% RH to 30% RH.
    Type: Grant
    Filed: August 13, 2018
    Date of Patent: April 19, 2022
    Assignees: FUJIFILM Business Innovation Corn., Daiichi Sankyo Company, Limited
    Inventors: Kensuke Ito, Yasuhiro Suzuki
  • Patent number: 11298359
    Abstract: To provide an antitumor drug having excellent therapeutic effect, which is excellent in terms of antitumor effect and safety. Provided is an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER3 antibody via a linker having a structure represented by the formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(?O)— or -L1-L2-LP- (the anti-HER3 antibody is connected to the terminal of L1, the antitumor compound is connected to the carbonyl group of —(CH2)n2-C(?O)— moiety or the C terminal of LP, with the nitrogen atom of the amino group at position 1 as a connecting position).
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: April 12, 2022
    Assignees: DAIICHI SANKYO COMPANY, LIMITED, DAIICHI SANKYO EUROPE GMBH
    Inventors: Thore Hettmann, Reimar Abraham, Sabine Blum, Suguru Ueno
  • Publication number: 20220106384
    Abstract: A novel peptide which comprises an amino acid sequence represented by SEQ ID NO: 23, and specifically inhibits the protease activity of a target molecule.
    Type: Application
    Filed: November 22, 2021
    Publication date: April 7, 2022
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Daisuke Nishimiya, Masakazu Tamura
  • Publication number: 20220106393
    Abstract: An object of the present invention is to provide a novel anti-CD147 antibody exhibiting potent antitumor efficacy and having excellent safety. Another object of the present invention is to provide a pharmaceutical product comprising such an antibody. Another object of the present invention is to provide a method for treating tumors using the antibody or the pharmaceutical product, for example. The present invention provides a CD147-specific antibody that activates CD147 and exhibits high antitumor efficacy. The present invention provides the anti-CD147 antibody that exhibits high antitumor efficacy independent of effector functions. The present invention provides a pharmaceutical composition comprising such an anti-CD147 antibody. The present invention provides a method for treating tumors using such an anti-CD147 antibody and/or pharmaceutical composition.
    Type: Application
    Filed: October 12, 2021
    Publication date: April 7, 2022
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Keisuke FUKUCHI, Kayoko NANAI, Masato AMANO, Kozo YONEDA, Yusuke TOTOKI, Shoji YAMAMOTO
  • Patent number: 11292828
    Abstract: SPINK2 mutant peptide conjugates are provided that inhibit KLK5. The KLK5 inhibitory peptide conjugates are Fc fusion peptides in which, in certain embodiments, the Fc region of the fusion peptides are the Fc region of human IgG1 or a fragment thereof. The KLK5 inhibitory peptide conjugates include an amino acid sequence of one of SEQ ID NOs: 34, 36, 38, 40, 42, 44, 46, 48, 96, 50, 52, 54, 56, 58, or 60. Pharmaceutical compositions that include the KLK5 inhibitory peptide conjugates useful for treating KLK5-related diseases are also provided.
    Type: Grant
    Filed: May 20, 2021
    Date of Patent: April 5, 2022
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Daisuke Nishimiya, Hidenori Yano, Hidenori Takahashi, Shinji Yamaguchi, Shiho Ofuchi
  • Publication number: 20220098235
    Abstract: To provide a method for purifying an antibody to a sufficient degree of purity for therapeutic use in humans by removing impurities contained in a solution efficiently while reducing production cost and the purification period in the purification of the antibody. It was found that an antibody can be reliably purified to a high degree of purity by an activated carbon material, regardless of the amounts or species of impurities co-present, and that high viral clearance can be attained reliably. Based on the finding, a treatment with an activated carbon material could be used in place of AEX chromatography achieving viral clearance in a step of purifying a therapeutic antibody using CHO cells. As a result, an antibody can be simply and effectively purified to a sufficient degree of purity for therapeutic use in humans compared to a conventional purification method, while reducing production cost.
    Type: Application
    Filed: January 22, 2020
    Publication date: March 31, 2022
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Yumiko MASUDA, Yuka OGINO, Kota INOUE, Kenta IZUMI, Chie MUTO
  • Patent number: 11274100
    Abstract: The present invention provides a compound having excellent histone acetyl transferase inhibitory activity against EP300 and/or CREBBP, or a pharmacologically acceptable salt thereof. The compound is represented by the following formula (1) or a pharmacologically acceptable salt thereof: wherein ring Q1, ring Q2, R1, R2, R3 and R4 respectively have the same meanings as defined in the specification.
    Type: Grant
    Filed: June 21, 2018
    Date of Patent: March 15, 2022
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Hiroyuki Naito, Yoshiko Kagoshima, Hideaki Funami, Akifumi Nakamura, Masayoshi Asano, Makoto Haruta, Takashi Suzuki, Jun Watanabe, Ryutaro Kanada, Saito Higuchi, Kentaro Ito, Akiko Egami, Katsuhiro Kobayashi
  • Patent number: 11273155
    Abstract: A pharmaceutical composition and a therapeutic method wherein an antibody-drug conjugate and an immune checkpoint inhibitor are administered in combination, and the antibody-drug conjugate is an antibody-drug conjugate in which a drug-linker represented by the following formula (wherein A represents the connecting position to an antibody) is conjugated to the antibody via a thioether bond; and a pharmaceutical composition and a therapeutic method for use in treatment of a disease that can be ameliorated through an antitumor immunity-activating effect wherein the antibody-drug conjugate is included.
    Type: Grant
    Filed: December 11, 2017
    Date of Patent: March 15, 2022
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Tomomi Iwata, Chiaki Ishii, Teiji Wada, Saori Ishida, Yasuki Kamai
  • Publication number: 20220072144
    Abstract: A therapeutic agent for HER3-mutated cancer containing an anti-HER3 antibody-drug conjugate as an active ingredient and/or a method of treatment for cancer, the method including administering an anti-HER3 antibody-drug conjugate to a subject determined to have HER3-mutated cancer.
    Type: Application
    Filed: September 19, 2019
    Publication date: March 10, 2022
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Kumiko KOYAMA, Yoshinobu SHIOSE, Suguru UENO
  • Patent number: 11261249
    Abstract: It is an object of the present invention to provide an anti-GPR20 antibody that can be used in the detection of GPR20, a reagent for GPR20 detection comprising the antibody, a reagent for diagnosis or a composition for testing of a disease related to the expression of GPR20, etc. The present invention provides an antibody specifically binding to a peptide comprising the amino acid sequence at amino acid positions 1 to 48 in SEQ ID NO: 1, or an antigen-binding fragment of the antibody, a chimeric antibody of the antibody, a rabbit type antibody of the antibody, etc. The present invention also provides a composition comprising the antibody, etc.
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: March 1, 2022
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Kenji Iida, Tomoko Shibutani, Kensuke Nakamura, Masato Amano
  • Patent number: 11261261
    Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety and has an excellent therapeutic effect, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER2 antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(?O)— wherein the anti-HER2 antibody is connected to the terminal L1, and the antitumor compound is connected to the carbonyl group of the —(CH2)n2-C(?O)— moiety with the nitrogen atom of the amino group at position 1 as the connecting position.
    Type: Grant
    Filed: August 19, 2020
    Date of Patent: March 1, 2022
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Hiroyuki Naito, Yusuke Ogitani, Takeshi Masuda, Takashi Nakada, Masao Yoshida, Shinji Ashida, Koji Morita, Hideki Miyazaki, Yuji Kasuya, Ichiro Hayakawa, Yuki Abe
  • Publication number: 20220040324
    Abstract: A pharmaceutical composition wherein an antibody-drug conjugate in which a drug-linker of the represented formula (wherein A represents a connecting position to an antibody) is conjugated to the antibody via a thioether bond and a kinase inhibitor (at least one selected from the group consisting of a CDK4/6 inhibitor, an mTOR inhibitor, a PI3K inhibitor, an AKT inhibitor, an ERK inhibitor, an MEK inhibitor, an RAF inhibitor, a CDK1 inhibitor, a CDK2 inhibitor, a CHK1 inhibitor, a WEE1 inhibitor, a PLK1 inhibitor, an Aurora kinase inhibitor, a Bcr-Abl inhibitor, an Src inhibitor, an EPH inhibitor, a VEGFR inhibitor, a KIT inhibitor, an RET inhibitor, a PDGFR inhibitor, an FGFR inhibitor, a BTK inhibitor, an FLT3 inhibitor, an ALK inhibitor, a JAK inhibitor, an MET inhibitor, a CSF-1R inhibitor, an NTRK inhibitor, an EGFR inhibitor, and an HER2 inhibitor) are administered in combination, and/or a method of treatment.
    Type: Application
    Filed: December 20, 2019
    Publication date: February 10, 2022
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Chiaki ISHII, Yasuki KAMAI, Kiyoshi SUGIHARA, Daisuke OKAJIMA, Yuuri HASHIMOTO, Hirokazu SUZUKI